Gilead Sciences: Its Game to Lose?

Gilead Sciences ( GILD ) won hepatitis-C in what amounted to a pyrrhic victory for the company . That leaves HIV as Gilead's most important business, a business that got a boost yesterday when the beaten-down biotech giant released data from a Stage 2 trial . As a result, "HIV is still Gilead's game to lose," says Piper Jaffray's Joshua Schimmer and team. They explain why: